Medical device manufacturer, Bedfont, who have specialised in breath analysis for more than 40 years, have announced a new and improved 2nd generation NObreath®. The FeNO monitor was launched exclusively at ERS, the world’s largest European Respiratory Society Congress, during September, in Paris.
The 2nd generation FeNO monitor is launched after the recent publication of the NICE guidance on Asthma: diagnosis, monitoring and chronic asthma management, to improve asthma care, which included the NObreath FeNO monitor from Bedfont as a recommended device [1,2].
Jason Smith, Managing Director, said: “As a breath analysis medical device manufacturer who exports globally, ERS is a key congress for us to reconnect with our customers from around the world. We are thrilled to be launching the 2nd generation NObreath exclusively at ERS this year as we feel it would be quite symbolic; this launch will bring the product full circle, as the very first NObreath was too launched at an ERS Congress 11 years ago. We’re excited to show our customers what’s in store for the advancement of respiratory care.”
REFERENCES
- Asthma: diagnosis, monitoring and chronic asthma management | Guidance and guidelines | NICE [Internet].Nice.org.uk. 2018 [cited 24 April 2018]. Available from: https://www.nice.org.uk/guidan
ce/ng80 - Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath | Guidance and guidelines | NICE [Internet]. Nice.org.uk. 2014 [cited 24 April 2018]. Available from:https://www.nice.org.uk/guidan
ce/dg12
